NANOBIOTIX Q1 Cash And Cash Equivalents €58.9M As Of March 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix reported cash and cash equivalents of €58.9 million as of March 31, 2024, which is expected to fund operations into Q3 2025, including a $20 million milestone received.
May 22, 2024 | 6:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanobiotix reported €58.9 million in cash and cash equivalents as of March 31, 2024, which will fund operations into Q3 2025, including a $20 million milestone received.
The reported cash position and funding into Q3 2025, including a significant milestone payment, provide financial stability and reduce short-term liquidity risks, likely positively impacting investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100